What should be done to improve the productivity of neurological research?

Annals of Neurology

Volumn 60, Issue 6, 2006, Pages 647-651

  Moses III, Hamilton ^a   Martin, Joseph B ^b  

^a Alerion Institute   (United States)

^b The Harvard Center for Neurodegeneration & Repair   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; FINANCIAL MANAGEMENT; FUNDING; INSTRUMENTATION; MEDICAL LITERATURE; MEDICAL RESEARCH; NEUROSCIENCE; PRIORITY JOURNAL; PRODUCTIVITY;

ACADEMIC MEDICAL CENTERS; ACCESS TO INFORMATION; ANIMALS; BIOMEDICAL RESEARCH; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; FINANCING, GOVERNMENT; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGY; NEUROSCIENCES; RESEARCH; RESEARCH SUPPORT;

EID: 33845972968     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21048     Document Type: Editorial

References (12)

1. Dorsey ER, Vitticore P, de Roulet J, et al. The financial anatomy of neurological research. Ann Neurol 2006;60:652-659.
2. Murray CJL, Lopez AD. The global burden of disease. Geneva: World Health Organization. 1996:261-271.
3. McColl DJ. The paucity of grants among young scientists. Science 2002;298:2328-2329.
4. Morrison E. Solving unsuspected problems. 1974. Reprinted in Rhodes R. Visions of technology (Sloan Foundation Series). New York: Simon and Schuster, 1999:319-321.
5. Ridley M. Eminent lives: Lrancis Crick. New York: Harper Collins, 2006:191-205.
6. Moses H, Braunwald E, Martin JB, Thier SO. Collaborating with industry: choices for the academic medical center. N Engl J Med 2002;347:1371-1375.
7. Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003;2:369-378.
8. Institute of Medicine. Drug discovery, development, and translation. Available at: http://www.iom.edu/CMS/3740/24155.aspx. Accessed September 25, 2006.
9. Crowley WF, Sherwood L, Salber P, et al. Clinical research in the US at a crossroads. JAMA 2004;291:1120-1126.
10. Wood AJJ. A proposal for radical changes in the the drug approval process. N Engl J Med 2006;355:618-623.
11. Steinbrook R. Wall Street and clinical trials. N Eng J Med 2005;353:1091-1094.
12. Lessons in the development of new antitubercular drugs: Global Alliance for TB Drug Development (2000 and 2006). Available at: http://www.stoptb.org/ Working_Groups/alliance.html. Accessed November 1, 2006.